Sharp Belgium, located in Flanders’ Limburg region, will package the biotech company’s products for the European market. Leveraging Flanders’ strategic location and excellent logistics system, Sharp Belgium offers many assets for Alnylam’s activities in the European market.
US biotech company Alnylam is specialized in RNAi therapeutics, a groundbreaking medical technology that serves as the basis for treatments that target rare diseases. Two products have already been developed, and RNAi therapy is currently being applied in the search for a medicine that prevents COVID-19 patients from infecting other people.
Alnylam hopes to submit its case to the FDA by the end of this year. Whether the COVID-19 medicine will be packed in Flanders upon release has not been disclosed yet.
